Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.

    ... Lenalidomide has proven efficacy and safety and has been shown to reduce ... System low- or intermediate-1-risk MDS who began lenalidomide therapy between April 2002 and June 2003 as part of the MDS-001 ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.

    ... Lenalidomide is an effective drug in low-risk myelodysplastic syndromes ... on treatment response and disease progression in 52 lenalidomide-treated patients with del(5q) MDS, conventional G-banding ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?

    ... agents, and the duration of response is often limited. Lenalidomide , a second-generation immunomodulatory drug (IMiD), is ... MDS patients with deletion 5q chromosomal abnormality. Lenalidomide also has meaningful clinical activity in lower-risk patients ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.

    ... immunomodulatory agents (imids) thalidomide and lenalidomide may induce transfusion independence . This guideline ... abstracts met eligibility criteria. CONCLUSIONS: Lenalidomide is recommended as first line therapy in lower risk del5q MDS. ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

    ... Lenalidomide was approved by the US Food and Drug Administration (FDA) for ... and frequency of myelosuppression. In del(5q) patients, lenalidomide suppresses the clone by inhibiting the nuclear ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.

    ... dependence. Over recent years, the immunomodulatory drug lenalidomide has demonstrated remarkable efficacy in patients with del(5q) ... of the pathogenesis of the disease have suggested that lenalidomide targets aberrant signaling pathways caused by haplosufficiency of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

    ... Lenalidomide and azacitidine each have activity in ... therapy with azacitidine (75mg/m(2)/d x 5 days) and lenalidomide (10mg/d x 21 days (28-day cycle)) in patients with higher-risk ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes

    ... Lenalidomide leads to high rates of erythroid transfusion independence ... parameters and TP53 mutations. These data also indicate that lenalidomide per se is not leukemogenic. Length of treatment can be tailored ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... Lenalidomide (LEN) has been shown to yield red blood cell (RBC) ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia-a wise Liaison?

    ... Currently, combination therapies of azacitidine with lenalidomide appear to be promising thus making them an appealing option ...

    Research Article last updated 07/20/2018 - 5:15pm.